162 related articles for article (PubMed ID: 36982571)
21. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
22. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis.
Zhao GX; Zhang Z; Cai WK; Shen ML; Wang P; He GH
Epilepsy Res; 2021 Jul; 173():106615. PubMed ID: 33756436
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
24. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
25. Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients.
Tang J; Xu J; Zhang YL; Liu R; Liu MZ; Hu YF; Shao MJ; Zhu LJ; Cao S; Xin HW; Feng GW; Shang WJ; Meng XG; Zhang LR; Ming YZ; Zhang W; Zhou G
J Clin Pharmacol; 2019 Jun; 59(6):890-899. PubMed ID: 30861159
[TBL] [Abstract][Full Text] [Related]
26. Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
Jabir RS; Ho GF; Annuar MABA; Stanslas J
Clin Breast Cancer; 2018 Oct; 18(5):e1173-e1179. PubMed ID: 29885788
[TBL] [Abstract][Full Text] [Related]
27. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of
Song H; Bai W; Sun X; Qiu B; Guo N; Guo C; Hu Y; Dong Z
Xenobiotica; 2021 Dec; 51(12):1463-1469. PubMed ID: 34979850
[TBL] [Abstract][Full Text] [Related]
28. The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
Furuse M; Hosomi S; Nishida Y; Itani S; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Watanabe T; Watanabe K; Fujiwara Y
PLoS One; 2021; 16(4):e0250597. PubMed ID: 33886687
[TBL] [Abstract][Full Text] [Related]
29. First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YA; Zhou BT
J Pharm Pharm Sci; 2015; 18(3):256-65. PubMed ID: 26517132
[TBL] [Abstract][Full Text] [Related]
30. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer.
Reed N; Glen H; Gerrard G; Good J; Lei M; Lyon AR; Strachan M; Wadsley J; Newbold K
Clin Oncol (R Coll Radiol); 2020 May; 32(5):e145-e153. PubMed ID: 31843241
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
[TBL] [Abstract][Full Text] [Related]
32. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
33. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.
Bustos ML; Zhao Y; Chen H; Caritis SN; Venkataramanan R
Pharmacotherapy; 2016 Dec; 36(12):1238-1244. PubMed ID: 27809336
[TBL] [Abstract][Full Text] [Related]
35. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
36. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
39. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
40. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Sychev DA; Sokolov AV; Reshetko OV; Fisenko VP; Sychev IN; Grishina EA; Bochkov PO; Shevchenko RV; Abdullaev SP; Denisenko NP; Ivashchenko DV; Sozaeva ZA; Kachanova AA
Pharmacogenet Genomics; 2022 Dec; 32(9):301-307. PubMed ID: 36256705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]